Epic has formed a partnership with molecular science company Caris Life Sciences for integration of its portfolio of services into Epic’s network. The partnership means that Epic will have access to ...
SAN DIEGO--(BUSINESS WIRE)--Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F ...
Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society ...